[Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
D000284:Administration, Oral; D001593:Benzyl Compounds / Q000008:administration & dosage; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects*; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism
D001593:Benzyl Compounds; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D004298:Dopamine
Terapéutica del sindrome de Parkinson por la L dopa per os asociada a un inhibidor de la descarboxilasa (Ro 46.02.